The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.
By T. Zaoutis, J. Argon, Jaclyn H. Chu, Jesse Berlin, T. Walsh, Chris Feudtner. Clinical Infectious Diseases, 2005
819 citations recorded by the source corpus.
Subfields: Immunology, Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/9b888fd6031a6958334de48793daec2bde4e57e8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
In Infectious Diseases
In Oncology
Citations in the corpus
- Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America (2009, background): “Invasive candidiasis has a significant impact on patient outcomes, and it has been estimated that the attributable mortality of invasive candidiasis is as high as 47% [11], although many authorities estimate the attributable mortality to be 15%–25% for adults and 10%–15% for neonates and children [1”
- Systematic screens of a Candida albicans homozygous deletion library decouple morphogenetic switching and pathogenicity (2010, background): “Below, we summarize insights gained from systematic screens of the library for (1) host (kidney) colonization, (2) the yeast-to-hypha transition, and (3) rate of proliferation in vitro.”
- Candida Infections of the Genitourinary Tract (2010, background): “In cases where candiduria leads to candidemia, the costs would rise dramatically, since candidemia results in an increase of perpatient hospital charges of up to $39,331 for adults and $92,266 for children (204, 289).”
- Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. (2007, neutral): “1086/520980 neonates and children [1, 9, 10].”
- Epidemiology of Invasive Mycoses in North America (2010, background): “It is also well known for causing infections in infants and neonates (Table 9) (Fridkin et al. 2006; Kuhn et al. 2004; Levy et al. 1998; Lupetti et al. 2002; Pfaller et al. 2008d; Reiss et al. 2008; Saiman et al. 2000; Sarvikivi et al. 2005; Saxen et al. 1995; Trofa et al. 2008; Van Asbeck et al. 20”
- Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. (2009, background): “Attributable mortality has been reported to range from 5% to 71%, and crude mortality rates have been reported to be as high as 81% [11–23].”
- Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007, background): “Those investigators used the database of the National Nosocomial Infections Surveillance system to show an overall decline in the frequency of BSIs due to Can- dida among ICU patients in the United States.”
- Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Candida bloodstream infections are associated with increased ICU and hospital stay [129, 235].”
- Hospital Epidemiology and Infection Control in Acute-Care Settings (2011, background): “The incidence of invasive candidiasis increased 15-fold between the 1970s and the 1990s (164, 257), and it has been estimated that the health care costs associated with invasive candidiasis in the United States total $2 billion to 4 billion per year (352, 366).”